Cardiome Pharma Announces Closing of Underwriters' Over-Allotment Option

Cardiome Pharma Corp. announced that the underwriters of its recently completed public offering have exercised their over-allotment option in full, purchasing an additional 1,275,000 common shares for gross proceeds of approximately US$7.6 million. All of the over-allotment shares were sold by the company. The combined gross proceeds to the company of the public offering and the exercise of the over-allotment option totaled approximately US$58.6 million.

Yahoo News (http://biz.yahoo.com/prnews/050330/to097.html?.v=2)